Abstract

Purpose The Zilver PTX drug-eluting stent (Cook Ireland Ltd., Limerick, Ireland) represents an advance in endovascular treatments for atherosclerotic superficial femoral artery (SFA) disease. Clinical data demonstrate improved clinical outcomes compared to bare-metal stents (BMS). This analysis assessed the likely impact on the French public health care budget of introducing reimbursement for the Zilver PTX stent.

Methods A model was developed in Microsoft Excel to estimate the impact of a progressive transition from BMS to Zilver PTX over a 5-year horizon. The number of patients undergoing SFA stenting was estimated on the basis of hospital episode data. The analysis from the payer perspective used French reimbursement tariffs. Target lesion revascularization (TLR) after primary stent placement was the primary outcome. TLR rates were based on 2-year data from the Zilver PTX single-arm study (6 and 9 %) and BMS rates reported in the literature (average 16 and 22 %) and extrapolated to 5 years. Net budget impact was expressed as the difference in total costs (primary stenting and reinterventions) for a scenario where BMS is progressively replaced by Zilver PTX compared to a scenario of BMS only.

Results The model estimated a net cumulative 5-year budget reduction of €6,807,202 for a projected population of 82,316 patients (21,361 receiving Zilver PTX). Base case results were confirmed in sensitivity analyses.

Conclusion Adoption of Zilver PTX could lead to important savings for the French public health care payer. Despite higher initial reimbursement for the Zilver PTX stent, fewer expected SFA reinterventions after the primary stenting procedure result in net savings.

Keywords Budget impact model · Drug-eluting stent · Paclitaxel-eluting stent · Peripheral artery disease · Superficial femoral artery

Introduction

Peripheral artery disease (PAD) is a progressive, lifestyle-limiting condition with prevalence in the range of 3–10 %, although it increases to 15–20 % in patients over 70 years of age [1]. Risk factors such as smoking, obesity, diabetes, hypertension, and age suggest that the prevalence of PAD...
in modern societies could be increasing [2]. Although most patients with PAD do not have symptoms, a proportion will develop symptomatic disease that manifests as pain in the leg muscles with exercise (intermittent claudication) and pain at rest, or skin lesions such as ulcers and gangrene (critical limb ischemia) [1].

Management of PAD is conditioned on a number of factors such as patient symptoms, patient characteristics (such as gender, age, smoking, obesity, cardiovascular risk factors), response to lifestyle and risk factor modification, and long-term prognosis [3–6]. Bypass surgery has been widely used to treat patients with critical limb ischemia and at a risk of limb loss, or those with longer or more complicated lesions. However, as a major surgical procedure, it has been associated with high morbidity and mortality as well as considerable resource use [7, 8]. Endovascular therapies are now commonly used to achieve revascularization in patients with intermittent claudication or critical limb ischemia where conservative therapy has not been successful. Within the endovascular treatment spectrum, percutaneous transluminal balloon angioplasty (PTA) is the simplest and least resource intensive procedure. PTA is, however, associated with high 1-year restenosis rates that worsen with longer and more complex lesions. Reported results vary widely, with 1-year patency rates for PTA ranging from 37 to 80 % [1, 9].

More recently, self-expanding nitinol bare-metal stents (BMS) have demonstrated improved patency results, yet restenosis remains a limitation [9–12].

Success in coronary artery intervention has led to investigation of drug-eluting stents in the superficial femoral artery (SFA). The Zilver PTX drug-eluting stent (Cook Ireland Ltd., Limerick, Ireland) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above-the-knee femoropopliteal arteries. Zilver PTX was recently evaluated in a large multicenter, multinational randomized, controlled trial and a complementary multinational, multicenter, single-arm clinical study [13–15]. The technology met the safety (12-month event-free survival) and effectiveness (primary patency) end points in these studies. Furthermore, results from the Zilver PTX randomized study demonstrated superior performance compared to PTA and compared to the identical bare-metal Zilver stent [13].

At a time when health care costs continue to escalate and budgets are under scrutiny, it is important to understand the impact of new technologies on health care spending. Whereas some innovations will increase the overall cost of treating patients, while improving survival and/or quality of life, the a priori perception that all innovation adds cost to the system is often the result of a short-term assessment of the impact on health care budgets, rather than evaluating the medium- to long-term cost consequences. The present budget impact assessment was conducted to inform the reimbursement decision for Zilver PTX in France. It demonstrates the 5-year budget impact of a progressive shift from BMS to Zilver PTX.

Materials and Methods

The budget impact model was constructed in Microsoft Excel. Because the model was originally developed as part of a reimbursement application to the French national health care authorities, the perspective is the third-party payer. The impact on the public health care budget of gradually adopting Zilver PTX in France was compared to the scenario where only BMS would be available in situations where stent placement would be the standard of care, with the model only considering BMS as a class as opposed to specific BMS types. The published decision on Zilver PTX reimbursement in France, as with many other implant devices listed in the French Liste des Produits et Prestations Remboursables (LPPR), is valid for a 5-year period [16]. Therefore, a 5-year model time horizon was chosen, with a new patient cohort entering the model each year from 2012 until 2016. Net budget impact was expressed as the difference in cost between the scenarios where Zilver PTX is progressively adopted versus BMS only.

Eligible Population

French national hospital episode statistics from the Agence Technique de l’Information sur l’Hospitalisation (ATIH) were used to estimate the patient population [17]. As a first step, the total number of lower limb peripheral stenting procedures performed in 2010 was determined [17].

However, the published reimbursement decision states that Zilver PTX reimbursement should be limited to patients with symptomatic atherosclerotic occlusive disease of the lower extremities, when used to treat lesions (length ≤14 cm) in the femoropopliteal arteries above the knee having a reference vessel diameter ranging between 4 and 9 mm, after failure of PTA [18]. Furthermore, the identified relevant procedure codes describe lower limb stenting procedures in general, but are not specific to any one artery in particular. According to the French authorities, the target patient population for SFA stenting with Zilver PTX was estimated to be about half (48 %) of the total number of lower limb stenting procedures performed as per 2008 data [18]. This percentage was applied to the total number of relevant procedures performed in the latest year for which ATIH data are available (2010). It was assumed that the target population would grow at a flat 10 % annual rate in subsequent years, which was informed by the percentage annual growth in procedures up to 2010. According to these estimations, the total patient population eligible for SFA stenting in 2012 is 13,483 patients. The build-up of the model patient population is summarized
in Fig. 1. In 2012, the impact of the reimbursement decision is expected to result in a market penetration rate of 15 \%, or 2,022 patients. Moreover, it is expected that the annual growth rate in adoption of the new technology over the time horizon of the budget impact model is constant and equals 5 \% per year after 2012, to yield a cumulative market penetration of 35 \% by 2016.

Model Structure

A new cohort of patients eligible for initial stenting enters the model each year, and patients in that cohort are treated either with Zilver PTX or BMS. As a result of restenosis of the treated lesion or lesions, a patient may need a reintervention at some point in time. The model used target lesion revascularization (TLR) rates for Zilver PTX and BMS in order to estimate the number of reinterventions and associated costs each year. Therefore, for any given year, the total number of patients needing a reintervention includes patients who have entered the model in that year as well as patients who received the initial stenting procedure in a previous year. The model assumes that a patient is not eligible for more than one reintervention procedure and does not die over the 5-year model time horizon. In the event of needing a reintervention, patients are treated with one of the following procedures: PTA; stenting or bypass surgery. The distribution of reintervention options was estimated on the basis of the observed distribution of reinterventions from the Zilver PTX single-arm clinical study, which enrolled 787 patients internationally (Cook Medical, data on file). The total costs of treating the target population with Zilver PTX or BMS over 5 years were compared to the costs of treating the same patient population if only BMS were available, in order to assess the overall budget impact of introducing Zilver PTX in the French public health care system.

Clinical Data

In the absence of a head-to-head comparison of Zilver PTX and BMS at the time of model development, the 12- and 24-month TLR rates were extracted from the published literature on BMS \cite{10, 11, 19} and from 2010 interim data from the Zilver PTX single-arm clinical study \cite{14}. Interim data from the single-arm study were used because this was the trial with the longest-term (24-month) data for TLR and were the only published data available. Published data on 12-month TLR from the randomized study comparing safety and effectiveness of Zilver PTX with PTA and provisional BMS placement in SFA patients \cite{13} were used in a scenario analysis.

The performance of the Zilver PTX stent was compared with BMS in the treatment of femoropopliteal lesions on the basis of published BMS data through subset analyses of the Zilver PTX single-arm study population data with matching inclusion/exclusion criteria for each individual BMS study (Table 1) \cite{14}.

All three BMS studies reported 12-month TLR rates \cite{10, 11, 19}. Additionally, the RESILIENT study reported 24-month TLR data \cite{20}. The TLR rates for Zilver PTX in each of the matching registry subpopulations, based on interim analysis, were 6 \% at 12 months \cite{14}. For BMS, an average 12-month TLR rate of 16.3 \% was calculated across all three studies to serve as the base case value for BMS as a class (Table 2). At 24 months, the interim TLR rate for Zilver PTX was 9 \% for the subset of patients matched with the RESILIENT study (Table 1) \cite{14}. For BMS, an average 24-month TLR rate of 21.9 \% was calculated on the basis of the difference observed between 12- and 24-month TLR rates in the RESILIENT and Zilver PTX studies (Table 2). More recent 12-month data for the three matching registry subpopulations indicated lower TLR rates (4–5 \%) for Zilver PTX; thus, the rates used in

\begin{table}
\centering
\begin{tabular}{|c|c|}
\hline
\textbf{Number of lower limb stenting procedures (2010)} & \\
\hline
EEAF 002: & 1,940 \\
EEAF 004: & 9,236 \\
EEAF 006: & 9,737 \\
EEPF 001: & 2,453 \\
\hline
\end{tabular}
\end{table}
the model analysis are somewhat higher and therefore conservatively overestimate the need for reinterventions. The impact on model results of a reduction in the average TLR rates for BMS was explored in a scenario analysis using data for LifeStent from the RESILIENT study, which at the time of model development was the only study that reported 12- and 24-month TLR rates [2, 11, 20].

No publications were found reporting the 3-, 4- and 5-year TLR rates after stent implantation. Therefore, those rates were extrapolated on the basis of clinical expert opinion that 5 years after initial stent placement, about 40% of patients treated with BMS would have needed a reintervention. Absolute annual 6% increments were applied to BMS from year 2 onward and the same 6% increment after 24 months was also conservatively applied to the Zilver PTX group because no other data were available (Table 2). Thus, the clinical benefit of Zilver PTX is due to the lower TLR rates seen in the first 2 years after the primary procedure.

**Treatment Costs**

To reflect the third-party payer’s perspective, only direct medical costs, covering inpatient treatment, were calculated. This was based on the reimbursement tariffs for both

---

**Table 1** Literature comparison for TLR rates

| Study       | Inclusion criteria | BMS | Zilver PTX$^a$ |
|-------------|-------------------|-----|----------------|
| DURABILITY  | No in-stent       | 21% at 12 month | 6% at 12 month |
|             | restenosis        | (n = 134) | (n = 474) |
|             | Lesion length     | ≤14 cm |  |
|             | Rutherford 2–4    |        |  |
| FAST [11]   | De novo lesions: | 15% at 12 month | 6% at 12 month |
|             | length            | (n = 127) | (n = 282) |
|             | 1–10 cm           |        |  |
|             | Multiple lesions  | ≤10 cm total |  ≥70% stenosis diameter |  |
| RESILIENT   | No in-stent       | 13% at 12 month | 6% at 12 month |
|             | restenosis        | (n = 153) | (n = 467) |
|             | Lesion length     | <15 cm |  |
|             | Rutherford 1–3    | 20% at 24 month | 9% at 24 month |
|             |                  | (n = 153) | (n = 235) |

$^a$ TLR rates for Zilver PTX were calculated from matching registry subset analyses. The inclusion criteria within each of the BMS published studies were matched for the Zilver PTX single-arm study [14]

**Table 2** TLR and distribution of reintervention options after Zilver PTX or BMS

| Characteristic | Variable | Zilver PTX (%) | BMS (%) | Source |
|---------------|----------|----------------|---------|--------|
| Cumulative TLR rate | Year 1 | 6.0 | 16.3 | Zilver PTX: single-arm study data [14, 15]; BMS: calculated values |
|                | Year 2 | 9.0 | 21.9 |  |
|                | Year 3 | 15.0 | 27.9 | Table 1 and expert opinion |
|                | Year 4 | 21.0 | 33.9 |  |
|                | Year 5 | 27.0 | 39.9 |  |
| Type of reintervention | PTA | 56 | | Zilver PTX: Cook, Zilver PTX single-arm study, data on file; BMS: assumption |
|                | Stent | 32 | |  |
|                | Surgical | 12 | |  |

If stent required

Zilver PTX | 25 | Expert opinion |

BMS | 75 |  |

If surgical intervention

Synthetic graft | 28 | Bradbury et al. [21] |

Patient’s vein | 72 |  |

If synthetic graft used, proportion by type:

Linear or nonlinear textile implant <30 cm | 60 | Expert opinion |

Linear or nonlinear textile implant ≥30 and <70 cm | 40 |  |

---

TLR target lesion revascularization, BMS bare-metal stent, Zilver PTX Zilver PTX drug-eluting stent (Cook Ireland Ltd., Limerick, Ireland), BMS bare-metal stent, PTA percutaneous transluminal balloon angioplasty
private and public hospitals, according to the French Groupe Homogène des Malades (GHM, a national diagnosis-related group system) [22] (Table 3). Because various GHM tariffs could apply to the episode of care for a patient requiring lower limb stenting, procedure codes relevant to lower limb stenting were identified, numbers of procedures were mapped to specific GHM codes for 2010 [17], and a weighted GHM tariff was calculated, taking into consideration the proportion of procedures conducted in public versus private hospitals. Reimbursement fees for consultants and anesthetists in private hospitals [26] were also taken into account and added to the respective private GHM tariff [22]. Costs were based on 2011 reimbursement tariffs, with variability in key cost inputs explored in sensitivity analyses. Weighted procedure tariffs of PTA and bypass surgery were calculated by the same methodology. Key model cost inputs are summarized in Table 3.

As previously mentioned, the expected direct cost of a reintervention was calculated on the basis of the observed distribution of reinterventions from the Zilver PTX single-arm clinical study (Table 2) (Cook Medical, data on file). The choice of reintervention option is assumed independent from the type of stent used for the primary procedure. Therefore, the expected cost of a reintervention after Zilver PTX and BMS primary stenting procedures was assumed the same.

### Analyses

In line with principles of good practice for budget impact analysis, no discounting was applied as the analysis presents financial streams over time [27]. The impact of relaxing key assumptions on model results was assessed through a number of scenario analyses, as summarized in Table 4.

### Results

Under the base case assumptions, the progressive adoption of Zilver PTX is cost saving from year 1 onward. The model estimated a cumulative 5-year budget reduction of

---

**Table 3** Model cost inputs

| Treatment | Cost (€) | Source |
|-----------|---------|--------|
| Zilver PTX | 1,000.00 | LPPR reimbursement tariff, code 3141310 [23] |
| BMS | 841.52 | LPPR reimbursement tariff; code 3183194 [24] |
| Linear/nonlinear textile graft <30 cm | 336.61 | LPPR reimbursement tariff; code 3171860 [25] |
| Linear/nonlinear textile graft ≥30 to <70 cm | 541.50 | LPPR reimbursement tariff; code 3189423 [25] |
| Linear/nonlinear textile graft ≥70 cm | 658.58 | LPPR reimbursement tariff; code 3122608 [25] |
| Stent implantation | 3,082.00 | Weighted cost, 2011<sup>a</sup> |
| PTA | 3,225.00 | Weighted cost, 2011<sup>b</sup> |
| Surgery | 7,414.00 | Weighted cost, 2011<sup>c</sup> |

<sup>a</sup> Relevant GHM codes are 05K061: vascular stent no MI, level 1; 05K062: vascular stent no MI, level 2; 05K063: vascular stent no MI, level 3; 05K064: vascular stent no MI, level 4; 05K06T: vascular stent no MI, very short stay 0 or 1 day [22].

<sup>b</sup> Relevant GHM codes are 05K131: Endovascular procedures without stent, age above 17 years, level 1; 05K132: Endovascular procedures without stent, age above 17 years, level 2; 05K133: Endovascular procedures without stent, age above 17 years, level 3; 05K134: Endovascular procedures without stent, age above 17 years, level 4; 05K13 J: Endovascular procedures without stent, age above 17 years, ambulatory [22].

<sup>c</sup> Relevant GHM codes are 05C101: Major vascular surgery, level 1; 05C102: Major vascular surgery, level 2; 05C103: Major vascular surgery, level 3; 05C104: Major vascular surgery, level 4 [22].

---

**Table 4** Scenario analyses

| Variable | Scenario |
|----------|----------|
| Higher TLR rates after Zilver PTX stenting | 12-month TLR 9.5 % [13] |
| | 24-month TLR 12.5 % (estimated) |
| | 24-month TLR 12.7 % [12, 19] |
| Lower TLR rates after BMS stenting | 30 % reduction in costs for primary stenting procedure and reintervention |
| | 30 % increase in costs for primary stenting procedure and reintervention |
| | Increased number of Zilver PTX stents for primary stenting procedure |
| | 1.25<sup>a</sup> |
| Zilver PTX market share at year 5 | 2012: 10 % to 2016: 30 % |
| | Primary stenting: €2,158; reintervention: €2,774 |
| | Primary stenting: €4,007; reintervention: €5,151 |
| Zilver PTX market share at year 5 | 2012: 20 % to 2016: 40.53 %<sup>b</sup> |
| 8 % reduction in Zilver PTX and BMS tariffs | Zilver PTX: €920<sup>c</sup>; BMS: €774.20 (estimated) |

<sup>a</sup> This assumes that a maximum of 25 % of cases would require two stents within this population, where the maximum lesion length is 14 cm.

<sup>b</sup> To reach target population of 8,000 in 2016, in accordance with target population for Zilver PTX as defined by French authorities [18].

<sup>c</sup> In accordance with fixed tariff from March 30, 2013, onward as defined by French authorities [23].
€6,807,202 for a projected population of 82,316 patients, of which 21,361 received the Zilver PTX stent (Table 5).

The difference in stent cost between Zilver PTX and BMS is more than offset by the savings accruing from lower reintervention rates, and therefore less rehospitalization, in each of the 5 years after the primary procedure (Fig. 2). The model calculated that 2,572 reintervention events would be avoided over 5 years with the progressive adoption of Zilver PTX (or a reduction from 22,088 to 19,516 events). For a hypothetical patient starting treatment in 2012, estimated total cost, including primary stenting and expected reinterventions up to 5 years, was €5,503 when a BMS was used, compared to €5,152 with Zilver PTX (difference of €351).

Scenario analyses indicated that the adoption of Zilver PTX results in cumulative 5-year budget reduction regardless of scenario (Fig. 3). Increasing the average number of Zilver PTX stents to 1.25 per patient for primary stenting yields the lowest net budget reduction. Although the use of lower TLR rates for BMS or higher 12-month TLR rates for Zilver PTX decreases budget savings in each year, 5-year cumulative budget offsets remain substantial. Faster uptake of Zilver PTX further increases annual budget savings because of the expected increased reduction in reinterventions. Similarly, the higher the primary stenting and expected reintervention cost, the higher are the budget savings associated with the use of Zilver PTX. To illustrate, increased costs could result from a larger share of bypass surgery reinterventions, or the need for some patients to undergo two angioplasty procedures for in-stent restenosis, leading to higher hospitalization costs.

**Discussion**

In September 2011, the French government published its decision to reimburse Zilver PTX [23] at €1,000 per stent, a 19% premium over the BMS reimbursement level. A higher tariff could suggest that this new technology would result in increased health care spending. However, as this budget impact analysis demonstrates, the expected reductions in restenosis and TLR rates not only provide clinical benefit to patients, but also help to avoid costly rehospitalization. The model suggests that budget offsets start within the first year of adoption and are sustained over the 5-year model time horizon.

Zilver PTX has demonstrated reductions in restenosis and TLR rates compared to the more traditional treatments of PTA and/or BMS [10, 11, 13–15, 19, 20]. This is an important clinical breakthrough in the treatment of atherosclerotic SFA disease. In today’s health care environment of ever-increasing demands on limited financial resources, health care decision makers—physicians, payers, and patients—increasingly want to understand the economic ramifications of new technologies. More and more, the questions being asked are “is it worth it?” and if so, “at what cost?”

**Table 5 Total and net 5-year budget impact**

| Time          | BMS only                                                                 | Progressive adoption of Zilver PTX                                                                 | Net annual budget impact (€) |
|---------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------|
|               | No. of procedures with BMS | Total treatment costs (€) | No. of procedures with Zilver PTX (% of total) | No. of procedures with BMS | Total treatment costs (€) | No. of procedures with BMS | Total treatment costs (€) |
| Year 1 (2012) | 13,483 | 61,632,893 | 2,022 (15 %) | 11,461 | 61,125,303 | -507,590 (-0.8 %) |
| Year 2 (2013) | 14,832 | 70,748,351 | 2,966 (20 %) | 11,865 | 69,801,480 | -946,871 (-1.3 %) |
| Year 3 (2014) | 16,315 | 81,028,788 | 4,079 (25 %) | 12,236 | 79,708,287 | -1,320,502 (-1.6 %) |
| Year 4 (2015) | 17,946 | 92,337,269 | 5,384 (30 %) | 12,562 | 90,577,880 | -1,759,389 (-1.9 %) |
| Year 5 (2016) | 19,741 | 104,776,598 | 6,909 (35 %) | 12,832 | 102,503,749 | -2,272,850 (-2.2 %) |
| Total over 5 years | 82,316 | 410,523,900 | 21,361 (26 %) | 60,956 | 403,716,697 | -6,807,202 (-1.7 %) |

Values are undiscounted; minus sign signifies reduction in annual budget.
There have been some attempts to assess the costs of treating patients with PAD. Mahoney et al. [2] compared the 2-year rates of vascular-related hospitalizations and associated costs in US patients with established PAD across patient subgroups. They concluded that the economic burden of PAD is high as a result of recurring hospitalizations and repeat revascularization procedures. A health care cost utilization study in the United States [28] attempted to assess the cost per day of patency after vascular reconstruction, and to determine if the initial cost savings of endovascular procedures were sustained over time. Although it concluded that the initial cost savings of endovascular therapies were not sustained, this analysis was limited to a 12-month time horizon and bundled all endovascular modalities (angioplasty, stenting, atherectomy or cryoplasty) into one group. The study was also limited by its retrospective nature and moderate sample size. In 2010, the authors of a review article on new SFA treatments [29] presented a hypothetical cost-calculation comparing the costs of using non-drug-eluting stents with drug-eluting stents. Although the review acknowledged the promise shown by preliminary clinical data for Zilver PTX, the cost analysis suggested that the stent would have an additional economic burden at 12 months after the procedure. However, the review has a number of limitations: (1) the underlying assumptions and methodology are unclear; (2) the sources for the hypothetical stent costs as well as for the reintervention profiles considered are not disclosed; and (3) the review used patency rates to calculate the number of repeat revascularization procedures, despite TLR rates being the more appropriate outcome.

As with any model, varying degrees of uncertainty exist around key model inputs. Model parameters were derived from previously reported studies and clinical trial data, supplemented by expert clinical opinion where published evidence was not available. Some of these uncertainties were: (1) the lack of randomized controlled trials directly comparing TLR rates of the Zilver PTX stent and current generation BMS; (2) the absence of long-term comparative results; (3) the assumption that the reintervention distribution was constant over time; (4) assumptions surrounding the number of stents used per SFA stenting procedure and the rate of uptake of Zilver PTX in France; and (5) the future level of GHM and LPPR tariffs. However, the uncertainties around the above parameters were addressed by conducting scenario analyses, the results of which confirmed the robustness of the model base case.

Like any other modelling study, which aims to reflect a complex real-world situation, this model has limitations. Firstly, the model population is restricted to the subgroup of lower limb atherosclerosis patients and shorter lesions (length $\leq 14$ cm) and a reference vessel diameter between 4 and 9 mm, as per the French authority decision [18]. This may not allow extrapolation to other populations. Indeed, the analysis does not assess budget impact for patient populations with longer, more difficult lesions nor for Zilver PTX as a first-line treatment for diabetic patients and in-stent restenosis. Because it is particularly challenging to treat these subgroups of patients [30–33], it would be interesting to study the budget impact of the use of Zilver PTX in a wider population when more clinical evidence for such patients becomes available. Furthermore, the model only considers the patient population that is eligible for stenting and does not include populations where other treatments such as balloon angioplasty or bypass surgery are the standard of care. Although the analysis performed is

---

**Fig. 3** Five-year net budget impact with Zilver PTX scenario versus BMS only compared to base case. Scenario descriptions correspond with those in Table 4.
specific to the impact of switching from BMS to Zilver PTX when treating femoropopliteal disease, there are also other new treatments that may be interesting to consider from a budget impact perspective, such as drug-eluting balloons [34].

Secondly, the model base case does not use randomized controlled trial data to compare TLR rates between groups. Although such data offer a higher level of evidence than single-arm study data, these were not available at the time of model development when only 12-month TLR rates were published for the primary stenting arm in the Zilver PTX randomized study (TLR = 9.5 %) [13]. This was used in a scenario analysis, and results were not much different compared to the base case. A 24-month update on the Zilver PTX randomized study reported 12- and 24-month TLR rates for the secondary randomization of provisional Zilver PTX versus provisional BMS, both after failed PTA (12-month TLR of 5.3 vs. 17.6 % and 24-month TLR of 10.8 vs. 23.1 %, respectively) [35]. The difference in 24-month TLR rates for provisional Zilver PTX and provisional BMS reported for the randomized study is very similar to the difference in the TLR rates from the interim analysis used in the budget impact model, which further strengthens the validity of the results.

Thirdly, in the absence of any long-term evidence (beyond 24 months), TLR rates for years 3, 4, and 5 were extrapolated assuming a constant 6 % absolute increase, which was informed by expert opinion estimating a cumulative 40 % TLR rate after primary stenting with BMS after 5 years. The validity of this assumption is confirmed by the recently published 3-year follow-up results from the RESILIENT trial, which indicated freedom from TLR of 75.5 % in the BMS group (equivalent to 24.5 % TLR compared to base case model average 3-year TLR of 27.9 %) [36].

Lastly, the model does not take into account mortality, as there was no clinical evidence suggesting a difference in survival between Zilver PTX and BMS. This has negligible impact on the reported budget reduction because the difference in cost between Zilver PTX and BMS groups is expected to remain constant with equal mortality.

Results from this study lend support to the argument that adoption of a somewhat more costly new technology can improve clinical outcomes while reducing expenditure, making both clinical and economic sense for the health care system to adopt the technology. To realize these benefits, it requires payers’ willingness to take a longer-term view of spending. It also demands that researchers and manufacturers involved with developing technology appreciate that health care budgets are not unlimited. These challenges can be met by both payers and manufacturers, as seen here with the adoption of the Zilver PTX stent in France, resulting in a reimbursement decision that can minimize financial hurdles for providers adopting the technology, ultimately benefiting the French patient.

**Conflict of interest** This research was carried out with financial support from Cook Medical. Marc Sapoval and Pierre Julia received an honorary fee for the work involved in expert consultation and manuscript development. Erwin De Cock and Greg de Lissovoy were employed by United BioSource Corporation (UBC) during the execution of this study. UBC provides consulting and other research services to pharmaceutical, device, government, and nongovernment organizations. In this salaried position, they work with a variety of companies and organizations. They receive no payment or honoraria directly from these organizations for services rendered. Sandra Lopes is an employee of William Cook Europe.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. Norgren L, Hiatt WR, Dormandy JA et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl 1):S1–S75
2. Mahoney EM, Wang K, Koo HH et al (2010) Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes 3:642–651
3. Gey DC, Lesbo EP, Mannhold J (2004) Management of peripheral arterial disease. Am Fam Physician 69:525–532
4. Hankey GJ, Norman PE, Eikelboom JW (2006) Medical treatment of peripheral arterial disease. JAMA 295:547–553
5. Hernandez-Vila EA (2011) Peripheral arterial disease in women: the effect of gender on diagnosis and treatment. Tex Heart Inst J 38:154–156
6. Steg PG, Bhatt DL, Wilson PW et al (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197–1206
7. Adam DJ, Beard JD, Cleveland T et al (2005) Bypass versus Angioplasty in Severe Ischæmia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet 366(9501):1925–1934
8. Gable D (2011) Role of total endoluminal superficial femoral artery bypass. J Cardiovasc Surg (Torino) 52:683–700
9. Schillinger M, Sabeti S, Loewe C et al (2006) Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354:1879–1888
10. Bosiers M, Torsello G, Gissler HM et al (2009) Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 16:261–269
11. Krankeborg H, Schluter M, Steinkamp HJ et al (2007) Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation 116:285–292
12. Laird JR, Katzen BT, Scheinert D et al (2010) Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 3:267–276
13. Duke MD, Ansel GM, Jaff MR et al (2011) Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4:495–504
14. Gray WA (2010) Two-year interim results from the single-arm clinical study of the Zilver PTX drug-eluting stent. Paper presented at society for cardiovascular angiography and interventions 33rd annual scientific sessions, San Diego, CA

15. Dake MD, Scheinert D, Tepe G et al (2011) Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 18:613–623

16. Ministère du travail, de l’emploi et de la santé (2011) Arrêté du 6 septembre 2011 relatif à l’inscription de l’endoprothèse périphérique à libération de principe actif (paclitaxel) Zilver PTX de la société COOK France au chapitre 1er du titre III de la liste des produits et prestations remboursables prévue à l’article L. 165-1 du code de la sécurité sociale. Journal officiel de la République française (JORF) no 27. Paris, France. http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=63ED0A58C70AA651A071D9BC7CDC4371.tpdjo11v_2?cidTexte=JORFTEXT000024543595&dateTexte=20110909&action=oldAction&categorieLien=id. Accessed 14 Sep 2011

17. Agence Technique de l’Information sur l’Hospitalisation (2012) Statistiques en ligne issues de la base nationale PMSI-MCO. Agence Technique de l’Information sur l’Hospitalisation. Lyon, France. http://www.atih.sante.fr/index.php?id=0004400001FF. Accessed 14 Sep 2011

18. Haute Autorité de Santé, Avis de la Commission Nationale d’Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) (2010) Zilver PTX, endoprothèse périphérique à libération de principe actif (paclitaxel). Haute Autorité de Santé. Saint-Denis La Plaine, France. http://www.has-sante.fr/portail/jcms/c_996539/zilver-pts-09-novembre-2010-2807-avis?xtmc=zilver&xtcr=1. Accessed 22 Aug 2011

19. KATZEN B, LAIRD J (2008) RESILIENT data: 1-year final results. Paper presented at 2008 international symposium on endovascular therapy (ISET-2008), Hollywood, FL

20. KATZEN BT (2008) Update and new findings from the RESILIENT trial comparing the (Bard) Lifesetent with POBA: is the improvement with stenting durable beyond 1 year? Paper presented at 35th annual VEITH symposium, New York, NY

21. BRADBURY AW, ADAM DJ, BELL J et al (2010) Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess 14:1–210, iii–iv

22. Ministère du travail, de l’emploi et de la santé (2011) Arrêté du 1er mars 2011 fixant pour l’année 2011 les éléments tarifaires mentionnés aux I et IV de l’article L. 162-22-10 du code de la sécurité sociale et aux IV et V de l’article 33 modifié de la loi de financement de la sécurité sociale pour 2004. Journal officiel de la République française (JORF) no 15. Paris, France. http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=63ED0A58C70AA651A071D9BC7CDC4371.tpdjo11v_2?cidTexte=JORFTEXT000023651050&dateTexte=20110909&action=oldAction&categorieLien=id. Accessed 26 Aug 2011

23. Ministère du travail, de l’emploi et de la santé (2011) Avis relatif aux tarifs et aux prix limites de vente au public en euros TTC d’un produit visé à l’article L. 165-1 du code de la sécurité sociale. Journal officiel de la République française (JORF) no 101. Paris, France. http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=63ED0A58C70AA651A071D9BC7CDC4371.tpdjo11v_2?cidTexte=JORFTEXT000024543595&dateTexte=20110909&action=oldAction&categorieLien=id. Accessed 14 Sep 2011

24. Sécurité Sociale—l’Assurance Maladie (2011) Gestion Risques Maladie. Liste des produits et prestations. Sécurité Sociale—l’Assurance Maladie. Paris, France. http://www.codegrex. cnamts.fr/cgi/tips/cgi-fiche?p_code_tips=3183194&p_date_jo_arrete=%25&p_menu=FICHE&p_site=. Accessed 29 Aug 2011

25. Sécurité Sociale—l’Assurance Maladie (2011) Gestion Risques Maladie. Liste des produits et prestations. Sécurité Sociale—l’Assurance Maladie. Paris, France. http://www.codegrex. cnamts.fr/cgi/tips/chapitre/index_chap.php?p_ref_menu_code=552&p_site=. Accessed 29 Aug 2011

26. Sécurité Sociale—l’Assurance Maladie (2011) Classification Commune des Actes Médicaux (CCAM) en ligne. La Caisse nationale de l’Assurance Maladie des travailleurs salariés (Cnamts). Paris, France. http://www.ameli.fr/accueil-de-la-ccam/index.php. Accessed 29 Aug 2011

27. MAUSKOPF JA, SULLIVAN SD, ANNEMANS L et al (2007) Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health 10:336–347

28. Stoner MC, Defreitas DJ, Manwaring MM et al (2008) Cost per day of patency: understanding the impact of patency and reinervention in a sustainable model of healthcare. J Vasc Surg 48:1489–1496

29. Bosiers M, Deloose K, Keirse K, Verbiest J, Peeters P (2010) Are drug-eluting stents the future of SFA treatment? J Cardiovas Surg (Torino) 51:115–119

30. Bosiers M, Deloose K, Callaert J et al (2011) Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 54:1042–1050

31. Dick P, Sabeti S, Mlekusch W et al (2008) Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 248:297–302

32. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M (2005) Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther 12:6–12

33. Zeller T, Macharzina R, Tepe G (2010) The potential role of DES in peripheral in-stent restenosis. J Cardiovas Surg (Torino) 51:561–565

34. Scheinert D (2010) Drug-eluting balloons in the SFA. Endovasc Today (March):42–44

35. ANSEL G (2011) Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Paper presented at CRT 2011, Washington, DC

36. LAIRD JR, KATZEN BT, SCHEINERT D et al (2012) Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 19:1–9